Advancing Precision RNA Therapeutics for Hurler Syndrome (MPS-1H)

Hurler syndrome (MPS I-H) is a severe lysosomal storage disorder caused by deficiency of alpha-L-iduronidase (IDUA), resulting in glycosaminoglycan (GAG) accumulation and progressive multisystem disease. Current disease-modifying care, especially early HSCT and adjunctive ERT, has improved survival and important clinical outcomes, but residual disease burden often persists across multiple tissues. This makes Hurler syndrome a strong first indication for a precision delivery strategy with translational platform value beyond a single programme.

Dawn positioning: DAWN-01 is framed as a focused preclinical Hurler programme while the underlying delivery platform is being built for broader use across rare disease, CNS, and musculoskeletal indications.

Clinical reality today

HSCT remains the standard disease-modifying pathway for severe Hurler syndrome, often alongside ERT and multidisciplinary specialist care. Early treatment is critical, but long-term morbidity can remain significant.

Why further innovation matters

Even with best current care, many patients continue to live with residual multisystem complications, including skeletal and other hard-to-correct manifestations. This is where improved tissue delivery could have major clinical value.

Platform fit

Hurler syndrome is well suited to a platform-led development model because it is biologically measurable (IDUA and GAG markers) and clinically challenging across multiple organs and tissues.

Pitch deck-derived evidence

Dawn’s Hurler programme is supported by two layers of evidence from the business plan: disease-specific DAWN-01 preclinical proof-of-concept in MPS1H models, and broader in vivo performance data from the targeted iLNP platform that demonstrates delivery strength across joint, cartilage, and CNS-relevant contexts.

MPS1H

Disease model proof-of-concept

Preclinical studies in MPS1H mice reported biomarker improvement, including normalisation of urinary GAG-related disease markers in treated animals. Dawn’s materials also describe no major early safety red flags in wild-type mice and a scalable vector manufacturing process established for translational development.

Biomarkers

Increase IDUA & Reduced GAGs

The recent research at Dawn Therapeutics reports significant increases in IDUA activity and broad tissue-level GAG reductions in preclinical models, including a mean reduction in heparan sulfate disaccharides and normalisation of urinary GAGs in treated animals.

Brain

Delivery Signal (platform evidence)

Dawn’s platform materials report strong BBB-related delivery performance in TfR-targeting datasets, including high brain exposure ratios in animal studies. A related peer-reviewed TfR-targeting conjugate study involving Dawn-linked authors also reports high brain-to-serum ratios and neuronal localisation in mice, supporting the broader CNS delivery rationale.

7-fold

Joint tissue expression gain

Targeted LNPs with joint-targeting antibodies reportedly increased gene expression about 7-fold in joint tissues in vivo.

5-fold

Joint NOTCH1 knockdown

An siRNA-loaded targeted LNP version reportedly achieved about 5-fold knockdown of NOTCH1 in joints in animal data.

8.5:1

Brain-to-plasma exposure ratio

Dawn reports a brain-to-plasma concentration ratio of 8.5:1 in animal models, supporting BBB-penetrant delivery capability.

1. Tissue-targeting performance matches the disease challenge

Hurler syndrome is not a single-organ condition. It affects the brain, skeleton, joints, airway, heart, and other systems. Dawn’s platform story is strongest where conventional delivery has historically struggled, especially cartilage, joint tissues, and CNS access. The reported in vivo cartilage transgene expression and joint delivery data are directly relevant to this disease biology.

2. Modality flexibility supports programme design

Dawn describes the iLNP platform as adaptable across replacement genes, mRNA, siRNA, and even CRISPR-related cargo types. For a Hurler-first programme, this gives the company scientific flexibility to optimise payload strategy over time while preserving the same delivery architecture and development learning.

3. DAWN-01 is a lead programme, not a one-off project

The business plan positions DAWN-01 as the first focused programme in a broader platform company. This is important scientifically because the lessons from Hurler disease development, including biodistribution, biomarker strategy, toxicology, and CMC, can strengthen future programmes in metabolic, musculoskeletal, and CNS indications.

4. A credible translational path is already defined

Dawn’s development plan is structured around staged non-clinical work, manufacturing transfer, toxicology, regulatory interactions, and CTA/IND-readiness milestones. That milestone discipline is a strong feature of the story because it keeps the Hurler programme technically focused and decision-driven.